Interviews with Pharma and Biotech Global Leaders
Refine Search
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Biotechnology
San Franciscan firm Cytokinetics is pursuing an unusual angle to therapeutic discovery, starting from an understanding of the biology of muscles in order to explore treatment options in different disease areas. 22 August 2017
Biotechnology
With the approval of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) in the USA and Europe last month, US biotech giant Gilead Sciences has now brought to market four hepatitis C virus (HCV) treatments, including three single-tablet regimens. 16 August 2017
Pharmaceutical
As the recent G20 Summit kicked off, in the midst of unprecedented civil unrest, advocates and lobbyists of every stripe descended on Hamburg in an effort to push their agenda. 10 August 2017
Pharmaceutical
Before 2012, Takeda Pharmaceutical did not have a presence in the global vaccines space. 4 August 2017
Biotechnology
While researchers have long tangled over the pathology of Alzheimer’s disease, recent trial failures have renewed interest in tau proteins as a therapeutic target. 26 July 2017
Pharmaceutical
The fall of solanezumab late last year, followed by verubecestat in February, sent tremors through the Alzheimer's research community and wiped billions from the share prices of those biologics’ respective developers - Eli Lilly and Merck & Co. 24 July 2017
Biotechnology
The perception that biomarkers will be key to unlocking the potential of precision medicine is so popular that they are now seen as an essential part of the drug development armory. 21 July 2017
Pharmaceutical
As a lifelong follower of the so-called ‘tau hypothesis’, TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years. 18 July 2017
Biotechnology
Biopharmaceutical research draws from a diffuse range of highly specialized technologies, and the traditional wisdom is that pharmaceutical firms, even very large companies, have little choice but to collaborate with others if they are to succeed. 4 July 2017
Pharmaceutical
Brexit, political instability, economic uncertainty, an aging population increasingly suffering from chronic conditions, a cost-effectiveness watchdog looking to save every penny possible when paying for new medicines and a National Health Service (NHS) reportedly facing its worst crisis in generations – the challenges facing the UK health sector appear almost insurmountable. 21 June 2017
Biotechnology
With EULAR in full swing in Madrid, much of the focus, as in other therapeutic areas, has been on the use of biomarkers to guide personalized treatment options. 16 June 2017
Biotechnology
In the run-up to EULAR, the leading congress in rheumatology, Dr Baker spoke to The Pharma Letter about the direction Janssen is taking. 13 June 2017
Biotechnology
At an unusually quiet annual meeting of the American Society of Clinical Oncology, Joanne Lager and Israel Lowy, the oncology heads of Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), found time to speak with The Pharma Letter to discuss progress in their long-standing collaboration. 12 June 2017
Biotechnology
As the annual meeting of the American Society of Clinical Oncology gets underway in Chicago, investors, competitors and industry watchers eagerly await results of Janssen’s LATITUDE trial of Zytiga in prostate cancer. 2 June 2017
Pharmaceutical
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole cancer product Erbitux (cetuximab) dropping to below $1 billion in 2016. 31 May 2017
Biotechnology
Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology, Michael Pehl says that: “We are really excited about the event - we have a really broad range of clinical data.” 26 May 2017
Biotechnology
While drug developers deserve credit for the enormous progress achieved in hepatology, use of the word ‘cured’ can perhaps be seen as unhelpful given that global statistics paint a very different picture of the impact of viral hepatitis. 22 May 2017
Biotechnology
France-headquartered Advanced Accelerator Applications is different not just because of its confidence in molecular nuclear medicine, but also because of its theragnostic approach, chief executive Stefano Buono tells The Pharma Letter. 8 May 2017
Biotechnology
In a claim that will make patient groups, PR companies and communication teams at pharma companies sit up and listen, the market access director for Swiss pharma giant Roche has said that pressure from the public and media was key to an innovative cancer drug being made available for Scottish women on the National Health Service (NHS). 27 April 2017
Biotechnology
Unusually for a biotech leader, chief executive Steve Holcombe had no previous experience or training in the life sciences when he joined vTv Therapeutics. 24 April 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze